Loading…
Recently listed biotechnology company; specific pipeline and disease focus not confidently known.
Recently listed biotechnology company; specific pipeline and disease focus not confidently known.
Moat: none
Size Braveheart Bio (BRVE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.67B, the 1914th largest of 3,117 United States companies the cockpit tracks. Shares closed at $18.60 on 6 Nov 2026.
Capital Return on invested capital runs 50.1 points below its cost of capital (6.4% WACC).
Short interest Short interest is 5.5% of the free float (15 Oct 2026).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | |
|---|---|---|
| Revenue | n/a | $0 |
| Revenue growth | — | — |
| Gross profit | n/a | $0 |
| EBITDA | n/a | -$65.4M |
| Net income | n/a | -$66.1M |
| Free cash flow | n/a | -$2.01M |
| Capital expenditure | n/a | $0 |
| Total debt | $575,000 | $0 |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BRVE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.6% | +0.7% | 9th lowest of 21 |
| Distance from 52-week high | -41.9% | -29.7% | 5th lowest of 21 |
| ROIC minus cost of capital | -50.1 pp | +1.7 pp | 3rd lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 4.7× | 6.7% | -4.3% |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 4.5× | 15.3% | +19.0% |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 1.2× | -6.0% | -5.6% |
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | 6.5× | 49.3% | +23.0% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 2.2× | -15.1% | +13.5% |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 2.6× | 3.1% | +9.9% |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 2.7× | n/a | n/a |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 2.2× | -4.5% | +6.8% |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 15.3× | 39.6% | +359.6% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | 3.7× | -4.1% | +0.2% |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 7.7× | n/a | n/a |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | 11.9× | n/a | n/a |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 5.9× | 14.7% | -14.0% |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | 18.4× | n/a | n/a |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 9.4× | 19.5% | +10.8% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 1.7× | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 3.4× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 9.6× | 37.6% | +16.6% |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 3.5× | -14.2% | +37.6% |